Central Serous Retinopathy: What You Need to Know

The retina is the light-sensitive tissue at the back of the eye that converts images into signals your brain can interpret. Directly beneath the retina sits the retinal pigment epithelium, a single layer of cells that nourishes the retina and pumps fluid away from it. When the RPE develops a tiny defect, serous fluid from the choroid (the vascular layer beneath the RPE) seeps through and pools under the central retina, creating a small blister-like detachment.

Most first-time episodes are classified as acute CSR. In acute cases, the fluid pocket typically reabsorbs within three to four months and vision returns to near-normal levels. Chronic CSR is diagnosed when fluid persists beyond this window or when repeated episodes cause lasting changes to the RPE. Over time, chronic CSR can lead to permanent thinning of the retina and measurable vision loss, making early monitoring essential.

Because CSR affects central vision, patients sometimes worry they may have age-related macular degeneration or a macular hole. While these conditions share some symptoms, CSR is driven by RPE leakage rather than drusen buildup or a structural break in the macula. Our retina specialists use high-resolution imaging to distinguish CSR from other conditions quickly and accurately.

Optical coherence tomography (OCT) is the primary tool used to visualize the fluid pocket beneath the retina. OCT provides cross-sectional images of the macula in fine detail, allowing us to measure the amount of fluid and monitor changes over time. Fluorescein angiography may also be performed to pinpoint the exact location of the RPE leak. In certain cases, indocyanine green angiography helps evaluate the choroidal circulation beneath the retina.

Because most acute episodes resolve spontaneously within a few months, careful observation with periodic OCT scans is often the first approach. During this time, we work with patients to identify and reduce modifiable risk factors such as corticosteroid use and unmanaged stress. If the fluid reabsorbs and vision recovers, no further intervention may be needed.

For chronic or recurrent CSR, photodynamic therapy (PDT) is one of the most effective treatments available. A light-activated medication called verteporfin is injected into a vein and then activated by a low-energy laser directed at the area of leakage. This process helps seal the RPE defect and reduce choroidal hyperpermeability. Reduced-fluence PDT, which uses a lower laser energy setting, has become the preferred approach because it minimizes the risk of collateral retinal damage.

Subthreshold micropulse laser therapy delivers very short pulses of laser energy to stimulate the RPE without causing a visible burn. This technique can encourage fluid reabsorption while preserving surrounding retinal tissue. It is an option for patients whose leakage point is located close to the center of the macula, where traditional laser could cause a permanent blind spot.

Mineralocorticoid receptor antagonists such as eplerenone and spironolactone have shown promise in reducing subretinal fluid in some chronic CSR patients. These medications work by blocking aldosterone receptors, which may play a role in choroidal vascular leakage. Our retina specialists may recommend a monitored trial of oral therapy when other treatments are not ideal or as a complement to laser-based approaches.